

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

CD271 (LNGFR)-VioBright FITC, human

RRID:AB_2661084

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-104-893, RRID:AB_2661084

Antibody Information

URL: http://antibodyregistry.org/AB_2661084

Proper Citation: Miltenyi Biotec Cat# 130-104-893, RRID:AB_2661084

Target Antigen: CD271 (LNGFR)

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 8-2018; Target Distribution B cells, bone marrow, cancer stem cells, dendritic cells, mesenchymal stem cells, monocytes, neurons; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-985. (RRID:AB_2734063).

Antibody Name: CD271 (LNGFR)-VioBright FITC, human

Description: This monoclonal targets CD271 (LNGFR)

Target Organism: other, non-human primate, human

Clone ID: ME20.4-1.H4

Antibody ID: AB_2661084

Vendor: Miltenyi Biotec

Catalog Number: 130-104-893

Record Creation Time: 20250820T053937+0000

Record Last Update: 20250820T220819+0000

Ratings and Alerts

No rating or validation information has been found for CD271 (LNGFR)-VioBright FITC, human.

Warning: Discontinued: 2021

Discontinued: 8-2018; Target Distribution B cells, bone marrow, cancer stem cells, dendritic cells, mesenchymal stem cells, monocytes, neurons; target type CD markers; tested applications MACS Flow Cytometry; quantity:

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-985. (RRID:AB_2734063).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Afsahi A, et al. (2023) LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling. Frontiers in immunology, 14, 1179827.